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Background
The aim of this study was to validate the Mantle cell lymphoma International Prognostic Index (MIPI) in a population-based cohort and to study the relevance of revisions.
Design and Methods
We analyzed data of 178 unselected patients with stage III or IV mantle cell lymphoma, registered between 1994 and 2006, in the Eindhoven Cancer Registry. Follow-up was completed up to January 1 st , 2008. Multiple imputations for missing covariates were used. Validity was assessed by comparing observed survival in our cohort to predicted survival of the original MIPI. A revised model was constructed with Cox regression analysis.
Discrimination was assessed by a concordance statistic ('c').
Results
The original MIPI could stratify our cohort into three distinct risk groups based on ECOG, WBC count, LDH level, and age, with discrimination nearly as good as in the original cohort (c 0.65 vs. 0.63). A modified model including performance status in five categories (0/1/2/3/4) instead of two (0-1/2-4), the presence of B-symptoms (yes/no) and sex (male/female) in addition to the original variables resulted in a better prognostic index (c 0.75).
Conclusions
The MIPI is a valid tool for risk stratification, comparison of prognosis, and treatment decisions in an unselected Dutch population-based setting. Although the MIPI can significantly be improved, external validation on an independent data set is warranted before broad application of this modified tool can be recommended.
Introduction
Mantle cell lymphoma (MCL) is a relatively rare lymphoma entity accounting for approximately 3% to 6% of all non-Hodgkin lymphoma (NHL) cases. It has a poor prognosis with a reported median overall survival (OS) of only 30 to 43 months. Treatment results have been unsatisfactory, although a substantial variation in outcome was noted among individual cases with some patients achieving long lasting remissions. 1 A validated prognostic index would greatly help in developing new treatment strategies based on risk and prognosis, and for evaluating and choosing between different available treatment options.
Recently, a new clinical prognostic index has been proposed for MCL: the Mantle cell lymphoma International Prognostic Index (MIPI). 1 This index is based on data derived from 3 large randomized clinical trials and proposes 3 risk groups according to the probability of survival. The score was defined on 455 patients. Several candidate prognostic factors were included, but parts of these were excluded in multiple regression, because of a high number of missing values.
In the original MIPI, a 4-variable model included the risk factors performance status (ECOG), white blood cell (WBC) count, lactate dehydrogenase (LDH) level, and age. 1 However, the MIPI has not been validated yet.
Validation is particularly important in a population-based setting to prove its use in a general health care environment containing more patients with advanced age and/or severe co-morbidity. Restrictive eligibility criteria, such as high age, serious comorbidity, poor performance status and impairment of organ function, might have biased this trial based series. 2 We previously found that comorbid conditions were present in 48% of unselected patients with aggressive NHL under age 60, and even in 79% of those older than 60. 3 Comorbidity, if serious enough, is an independent prognostic factor. [4] [5] [6] Moreover, we recently showed that the performance of the Follicular Lymphoma
International Prognostic Index (FLIPI) could significantly be improved by a more refined coding of age and by including the presence of cardiovascular disease. 7 We therefore considered that also performance of the MIPI might be improved by adding others risk factors, amongst others comorbidity.
The aim of this study was to validate the original MIPI in a population-based cohort and to study possibilities for improvement of the MIPI.
Design and Methods

Study population and data collection
The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the southern part of the Netherlands, an area with 2.4 million inhabitants, 10 general hospitals and two large radiotherapy institutes. 8 Treatment decisions were generally made in multi-disciplinary meetings, within the frame work of the comprehensive cancer centre. Trained registration clerks actively collect data on diagnosis, topography, histology, stage and information about initial treatment (delivered within 6 months from diagnosis) from hospital medical records. The medical record is generally regarded as the most complete source of information on the patient's past and current health status. 9 Since 1993 the Eindhoven Cancer Registry also registers the presence of serious comorbidity with prognostic impact at the time of cancer diagnosis, using a slightly modified version of the widely used Charlson comorbidity index. 4, 10 Comorbidity was defined as any other disease that was present at the time of cancer diagnosis. Comorbidities were registered as dichotomous variables (yes/no), according to the medical history of the patient, the use of relevant drugs and diagnostic work-up. Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) are diseases with significant influence on survival. and patients with score higher than or equal to 6.2 as high risk (HR). Survival time was defined as the time from diagnosis till death or the end of the study.
Statistical analysis
Missing values may occur selectively across patients. Exclusion of patients with missing values might hence bias the results. Therefore, we imputed missing covariates using correlations between variables. We used a multiple imputation (MI) procedure where each missing value was imputed 5 times. Imputed values were drawn from the predictive distribution in an imputation model that included all risk factors (age, LDH, total leukocyte and lymofcyte, granulocyte, trombocyte count, performance status, number of comorbidities, cardiovascular disease, COPD, sex, spleen involvement, B-symptoms, stage, albumine and hemoglobine) and the survival outcome.
Imputation of missing predictor values using the outcome is preferred over imputation without outcome and is no self-fulfilling prophecy. 12 The variation among the 5 imputations reflects the uncertainty with which the missing values can be predicted. Multiple imputations resulted in 5 completed datasets, which were analyzed with standard statistical methods. The results were combined to produce overall estimates and standard errors that reflected missing data uncertainty. 13 All analyses were performed for both complete cases as well as for single and multiple imputations. All results are reported with multiple imputed data, except for the Kaplan-Meier analyses, which were based on a single imputed data set. We checked the results of the randomly chosen single imputations, and those were comparable with the multiple imputation.
Validation of the MIPI started with a comparison of the hazard ratios (HRs) of the risk factors (refitted MIPI).
We checked whether the coefficients in the Cox regression equation needed to be updated, based on likelihood ratio (LR) statistics, 14 and for the categorical variables if other cut points should be used (revised MIPI). Next, we considered extension of the model with COPD (yes/no), CVD (yes/no), the number of comorbidities (yes/no or no/one/more than one), and a combination of these variables. We calculated the explained variation by the covariates as R 2 = 1 -exp (-LR/n). Furthermore we evaluated if sex, the presence of B-symptoms, stage, chemotherapeutic regimen, transplantation, hemoglobin level, beta-2-microglobulin level, albumin level and lymphocyte, granulocyte, monocyte and platelet count, and a combination of these variables could further improve the MIPI (modified MIPI). We used a stepwise approach, to include the variable who improved the model the most. Finally we tested the value of Ki-67 level, to validate the biological index of MIPI (MIPIb).
We used the c-statistic to study discrimination, which reflected to the ability of the (modified) MIPI to assign higher predicted risks to subjects who died during the follow-up than to subjects who survived during the follow-up period. We used a bootstrap resampling procedure to correct for statistical optimism in the c-statistic for the refitted and modified models. Modeling was repeated in 200 bootstrap samples, with model testing in the original sample. 15 Statistical analyses were performed using SAS software (version 9.1, SAS Institute Inc., Cary, North Carolina, USA, 1999), and R software (v 2.5.1, R Foundation for Statistical Computing, Vienna, Austria), with MI using the aregImpute function.
Results
Of the 181 stage III and IV MCL patients, three were excluded, because no sufficient information could be gathered. Our population-based study included more patients with advanced age and more patients with a lower performance status, as compared with the original MIPI study ( categories: low or < 10%, positive or 10%-29% and high or !30%.
In our study population 126 patients died, accounting for a 1 and 5-year survival rate of 80% and 34%
respectively, resulting in a lower median overall survival (OS) than in the original study (26 vs and 41%; and those in the high risk group had the worst OS: 68% and 20%, respectively. In our cohort the MIPI score discriminated nearly as good as in the original cohort (c 0.65 vs. 0.63).
While the discrimination of the whole model was comparable, the hazard ratio (HR) of performance status was somewhat higher, and the HR's of LDH level and WBC count were a little lower than in the original study ( (Figure 1 ).
For the biologic index (MIPIb) we tried to collect data on the proliferation marker Ki-67, but this marker was not tested or badly recorded in the medical records. For those cases with an available test on Ki-67 the positivity did not contribute to the MIPI, when divided in 4 categories. Also with multiple imputations of the missing Ki-67 values, no improvement in the MIPI was noted.
Discussion
Prognostic models should be valid for daily clinical practice, allowing risk stratification and comparison of prognosis, and thus forming a rationale for treatment decisions. Validation in population-based settings is important because it shows if a prognostic index is functional in daily practice. In our population-based setting the MIPI was valid, but the MIPI could significantly be improved by a more refined coding of performance status and by including the presence of B symptoms and sex as risk factors.
The most likely reason for the higher proportion of patients with advanced age in our population-based cohort is that the original report was based on data from clinical trials, with restrictive selection criteria. For instance the European MCL trial 16 had an age limit up to 65 years. Furthermore all three trials, [16] [17] [18] which formed the basis for the original study, excluded patients with serious concomitant diseases, poor performance status, or significant impairment of organ function. 1 We found the prognostic value of age to be independent from the presence of co-morbidity and performance status and therefore might reflect unknown co-morbid or pathophysiological conditions more frequently encountered in elderly patients with subsequent less tolerance for treatment.
In several studies comorbidity was found to be an independent prognostic factor for survival in NHL patients. 3, 6 Although the presence of comorbidity in general, and cardiovascular disease in particular, were significant prognostic factors in univariate analyses, these factors could not improve the prognostic performance of MIPI model. This is probably explained by the fact that performance status was included in the model, and this factor partly reflects the presence of comorbidity. 19 The higher proportion of patients with a poorer performance status in our study could also be the reason for the relatively low impact of performance status in the original model containing only very few patients with a poor performance status.
It remains to be debated whether the poor prognosis associated with advanced age and poorer performance status should be a reason for a different, more aggressive treatment approach, because previous studies have shown that these patients experience more side effects of treatment. 20 This should preferably be investigated prospectively.
Furthermore, studying cause-specific survival may also help to unravel this question, since part of the worse prognosis might also be due to mortality from the comorbidity itself.
The above mentioned factors could also be the explanation for the lower median survival in our study compared to the original study. 1 Of note, other population based studies showed a similar survival to our study. 21, 22 The prognostic effect of sex was not observed in the original study. 1 The incidence of MCL is known to be higher in males. 1, 21, 23 Although the prognostic effect of sex is not found in other studies, 1, 3, 21, 24 it did improve the MIPI significantly in our study. In diffuse large B-cell lymphoma the prognostic effect of sex was found after the introduction of Rituximab. 25 In this study only 4% of the patients was treated with Rituximab We therefore think that this does not explain the prognostic effect of sex. Since we cannot provide a good explanation for this effect, it is important to validate the modified MIPI, with sex as covariate, in other populations.
Another interesting observation in our study is that the presence of B-symptoms had an important prognostic effect and could improve the MIPI. This effect has also been reported in univariate analyses in some earlier studies, 1, 26 but disappeared in multivariable analyses, in contrast to other studies which have shown that it was an important independent risk factor, also in multivariable analyses. 21, 27 In our study the prognostic effect of the biological marker Ki-67 could not be tested reliably, because of a very high percentage of missing values and no specific coding in the medical records. The original study also showed a high percentage (48%) of missing values. Since recent studies report Ki-67 to be an important prognostic factor for mantle cell lymphoma patients, 24, 26, [28] [29] [30] it is important that the prognostic significance of Ki-67 in the MIPI model should be investigated.
The current analyses did not include patients with limited stage I or II MCL, because the MIPI was not designed for these patients. Hoster et al. 1 stated that the prognostic relevance of stage was not consistently seen in the literature. Moreover, the proportion of patients with stages I or II is rather low in MCL and they require a different therapeutic approach. Thus Hoster et al. limited their investigation to the advanced stage MCL patients with standardized treatment options (56% CHOP, 31% R-CHOP and 11% MCP). [16] [17] [18] This original data was also limited to patients who should tolerate moderately intensive chemotherapy. In our study the proportion of unselected patients receiving moderately intensive treatment was obviously lower, as compared to trial-based studies, as the original publication. More patients were treated with relatively mild regimens (43% CHOP (like), 15% RCHOP, 4% induction treatment for ASCT, 19% palliative chemotherapy and 18% no chemotherapy).
Treatment decisions are probably correlated with prognostic factors in our retrospective study. When we included treatment in our multivariate analyses, no additional prognostic value of treatment could be detected as compared with the other factors of MIPI, and therefore we can conclude that the other prognostic factors are more important for this patient population.
Several candidate prognostic factors were included in the original study, 1 but part of these were excluded in multiple regression, because of a high number of missing values. It is now widely recognized that complete case analyses with missing values in the data set can lead to bias of the results and are statistically inefficient.
13
Nowadays, application of methods for handling missing data is becoming more standard and software is more readily available. Multiple imputation is considered a sound statistical methodology for handling complex missing data problems, 13, 31 that contributes to statistically more reliable retrospective analyses, including ours.
In conclusion, the MIPI is a valid tool for risk stratification, comparison of prognosis, and treatment decisions in an unselected Dutch population-based setting. Although the MIPI can significantly be improved, external validation on an independent data set is warranted before broad application of this modified tool can be recommended.
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